|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Restricted short-term investments | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts receivable | ||||||||||||||||||||
| Accounts receivable - related parties | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Income tax receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net (accumulated depreciation of 33,598 and 31,696 as of June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Financing lease right-of-use assets | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill, net | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts payable | ||||||||||||||||||||
| Accounts payable - related parties | ||||||||||||||||||||
| Lines of credit | ||||||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||||||
| Operating lease liabilities, current portion | ||||||||||||||||||||
| Financing lease liabilities, current portion | ||||||||||||||||||||
| Accrued arbitration expenses | ||||||||||||||||||||
| Accrued income tax expense | ||||||||||||||||||||
| Accrued stock-based compensation | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt, net | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Non-current operating lease liabilities, net | ||||||||||||||||||||
| Non-current financing lease liabilities, net | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Common stock, $0.001 par value; 950,000,000 shares authorized; 6,951,622 and 5,511,452 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Nutex Health Inc. equity | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...